Halozyme Therapeutics Inc (HALO) Outlook Starting To Look Brighter?

Halozyme Therapeutics Inc (HALO) concluded trading on Wednesday at a closing price of $70.14, with 9.68 million shares of worth about $679.02 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.73% during that period and on May 07, 2025 the price saw a gain of about 18.12%. Currently the company’s common shares owned by public are about 123.17M shares, out of which, 122.23M shares are available for trading.

Stock saw a price change of 14.20% in past 5 days and over the past one month there was a price change of 18.18%. Year-to-date (YTD), HALO shares are showing a performance of 46.71% which increased to 75.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.87 but also hit the highest price of $66.00 during that period. The average intraday trading volume for Halozyme Therapeutics Inc shares is 1.48 million. The stock is currently trading 16.25% above its 20-day simple moving average (SMA20), while that difference is up 14.88% for SMA50 and it goes to 24.53% higher than SMA200.

Halozyme Therapeutics Inc (NASDAQ: HALO) currently have 123.17M outstanding shares and institutions hold larger chunk of about 99.64% of that.

The stock has a current market capitalization of $8.66B and its 3Y-monthly beta is at 1.26. PE ratio of stock for trailing 12 months is 18.61, while it has posted earnings per share of $3.77 in the same period. Its PEG reads 0.65 and has Quick Ratio of 7.30 while making debt-to-equity ratio of 3.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HALO, volatility over the week remained 5.07% while standing at 4.58% over the month.

Stock’s fiscal year EPS is expected to rise by 26.57% while it is estimated to increase by 33.81% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on October 07, 2024 offering an Equal weight rating for the stock and assigned a target price range of between $58 and $62 to it. Coverage by JP Morgan stated Halozyme Therapeutics Inc (HALO) stock as a Neutral in their note to investors on September 19, 2024, suggesting a price target of $57 for the stock. On June 07, 2024, Piper Sandler Downgrade their recommendations, while on February 29, 2024, TD Cowen Initiated their ratings for the stock with a price target of $54. Stock get a Buy rating from H.C. Wainwright on July 24, 2023.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.